GLP-1: what this gut hormone actually does
Before GLP-1 became a household name, it was just a short-lived peptide doing quiet, essential work in your digestive tract.
TL;DR
- GLP-1 is released by specialized cells in your small intestine every time you eat — it’s not a drug, it’s a hormone your body already makes.
- It works on three systems simultaneously: the pancreas, the stomach, and the brain — each one contributing to blood sugar regulation and appetite signaling.
- GLP-1-based therapies mimic this natural hormone; understanding the biology helps clarify both their effects and their limitations.
What it is
Glucagon-like peptide-1 (GLP-1) is a 30-amino-acid incretin hormone produced by L-cells in the distal small intestine and colon. Your body releases it within minutes of eating, and it has a circulating half-life of roughly 2 minutes before an enzyme called DPP-4 breaks it down. That brevity is part of why GLP-1 receptor agonist drugs were developed — they were engineered to resist that rapid degradation. The published science on endogenous GLP-1 goes back to the 1980s; its therapeutic relevance has been studied extensively since the early 2000s.
How it works
GLP-1 acts on at least three distinct targets simultaneously. First, it stimulates the pancreatic beta cells to release insulin — but only when blood glucose is elevated, which is why this is described as glucose-dependent. Second, it suppresses glucagon secretion from alpha cells, reducing hepatic glucose output. Third, and most relevant to weight-related research, it crosses into the central nervous system and acts on GLP-1 receptors in the hypothalamus and brainstem, where it is associated with reduced appetite signaling and slower gastric emptying — meaning food moves through your stomach more gradually, extending the sensation of fullness.
Who asks about it
People come to this topic when they’re trying to understand why GLP-1 therapies seem to work across multiple systems at once. The question is usually some version of: “Is this just a weight-loss drug, or is something more fundamental happening biologically?” That’s the right question to ask before any clinical conversation.
What the research says
Drucker’s foundational review in Cell Metabolism (2018) describes GLP-1 as a “pleiotropic hormone” with effects spanning the gut, pancreas, cardiovascular system, and central nervous system. Clinical trial programs studying GLP-1 receptor agonists — particularly the STEP series published in The New England Journal of Medicine — have examined how these downstream effects translate to outcomes in humans at varying doses. The cardiovascular outcomes data from the LEADER and SUSTAIN-6 trials added further context to the non-metabolic signaling arms of this pathway.
What to know before considering it
GLP-1 receptor agonist therapies require a licensed clinician evaluation and a valid prescription. They are not appropriate for everyone, and the published literature documents a range of commonly reported side effects including nausea, vomiting, and gastrointestinal symptoms. Any compounded formulation is prepared by a state-licensed 503A compounding pharmacy from an FDA-approved active pharmaceutical ingredient — compounded products are not themselves FDA-approved. Contraindications in the published literature include personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
The Halftime POV
Most people encounter GLP-1 first as a brand name and work backward. We think it’s more useful to start with the biology — to understand that the hormone itself is something your gut already produces, and that the therapy is working with a system your body built. That framing doesn’t change the clinical math, but it does change how you approach the conversation with a clinician. Knowing what the mechanism is makes for a better-informed patient.
Related reading:
FAQ
Q: What is GLP-1? A: GLP-1 (glucagon-like peptide-1) is a 30-amino-acid incretin hormone produced by L-cells in the distal small intestine and colon. Your body releases it within minutes of eating. Its circulating half-life is roughly 2 minutes before the enzyme DPP-4 breaks it down — the brevity of natural GLP-1 is why GLP-1 receptor agonist drugs were engineered to resist that degradation.
Q: How does GLP-1 affect appetite? A: GLP-1 crosses into the central nervous system and acts on GLP-1 receptors in the hypothalamus and brainstem, where it is associated with reduced appetite signaling and slower gastric emptying — meaning food moves through the stomach more gradually, extending the sensation of fullness. This is one of three simultaneous actions; GLP-1 also affects the pancreas and liver.
Q: Are compounded GLP-1 medications FDA-approved? A: No. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients — they are not themselves FDA-approved products. GLP-1 therapies require a valid prescription following a licensed clinician evaluation. Compounded GLP-1 products are also subject to ongoing litigation (Novo Nordisk v. Hims & Hers, Feb 2026).
Disclaimer
This article is educational and is not medical advice. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved. GLP-1 therapies are available only with a valid prescription following a licensed clinician evaluation. Clinical outcomes depend on individual factors including baseline health, adherence, diet, and physical activity. Individual results vary. Side effects are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Halftime Health is launching soon — join the waitlist to get updates.
Note on ongoing litigation: Compounded GLP-1 products are the subject of ongoing litigation (Novo Nordisk v. Hims & Hers, Feb. 2026). The regulatory landscape for compounded GLP-1 formulations continues to evolve.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
Sources
- Drucker DJ. “The biology of incretin hormones.” Cell Metabolism, 2006
- Drucker DJ. “Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.” Cell Metabolism, 2018
- Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” NEJM, 2021 (STEP 1)
- Marso SP, et al. “Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.” NEJM, 2016 (SUSTAIN-6)
